false
0001739174
0001739174
2025-10-17
2025-10-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 17, 2025
| BiomX Inc. |
| (Exact Name of Registrant as Specified in its Charter) |
| Delaware |
|
001-38762 |
|
82-3364020 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
22 Einstein St., Floor 4
Ness Ziona, Israel |
|
7414003 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: +972 723942377
| n/a |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
| Common Stock, $0.0001 par value |
|
PHGE |
|
NYSE American |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On October 16, 2025, BiomX Inc. (the “Company”)
held its 2025 Annual Meeting of Stockholders. At the meeting, stockholders voted in favor of all items of business, as indicated below:
Proposal No. 1- Election of Class II Directors.
The Company’s stockholders voted to approve the election of three
Class II directors to serve on the Company's Board of Directors until the 2028 annual meeting of stockholders.
| Nominee | |
Votes For | |
Votes Withheld | |
Broker Non-Votes |
| Susan Blum | |
13,944,681 | |
151,456 | |
0 |
| Dr. Jesse Goodman | |
12,394,563 | |
1,701,574 | |
0 |
| Gregory Merril | |
12,308,038 | |
1,788,099 | |
0 |
Proposal No. 2- Authorization of the Company's board of directors
to amend the certificate of incorporation to effect a reverse stock split of the Company’s outstanding Common Stock at any ratio
between at least 1-for-5 and less than 1-for-20.
The Company’s stockholders voted to approve the authorization
of the Company’s Board of Directors to amend the certificate of incorporation to effect a reverse stock split of the Company’s
outstanding Common Stock.
| Voted For | |
Voted Against | |
Abstain | |
Broker Non-Votes |
| 13,641,280 | |
383,712 | |
71,143 | |
N/A |
Proposal No. 3- Ratification of selection of independent registered
public accounting firm for fiscal 2025.
The Company’s stockholders voted to approve the ratification
of the selection of Kesselman & Kesselman, certified public accountants (Isr.), a member firm of PricewaterhouseCoopers International
Limited, as the Company’s independent registered public accounting firm for fiscal year 2025.
| Voted For | |
Voted Against | |
Abstain | |
Broker Non-Votes |
| 14,050,210 | |
25,633 | |
20,294 | |
N/A |
The Company did not call the vote on a proposal to adjourn the meeting,
as there were sufficient votes to approve all of the other proposals. The results reported above are the final voting results.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
BIOMX INC. |
| |
|
|
| October 17, 2025 |
By: |
/s/ Jonathan Solomon |
| |
|
Name: |
Jonathan Solomon |
| |
|
Title: |
Chief Executive Officer |
2